Related Experiment Video

Updated: Aug 29, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

The future of respiratory syncytial virus vaccine development

Fernando P Polack1, Ruth A Karron

  • 1Department of Intenational Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

The Pediatric Infectious Disease Journal
|January 20, 2004
PubMed

Insights

Developing a respiratory syncytial virus (RSV) vaccine remains challenging. While progress has been made with live attenuated and subunit vaccines, none are yet suitable for infants, necessitating further research.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract illness in infants and children.
  • Despite extensive research, no licensed RSV vaccines are currently available.
  • RSV disease impacts various age groups, highlighting the need for effective prevention.

Purpose of the Study:

  • To review obstacles in developing RSV vaccines.
  • To examine current live, attenuated, and subunit RSV vaccines in clinical trials.
  • To explore the potential of recombinant technology for novel vaccine candidates.

Main Methods:

  • Review of existing literature on RSV vaccine development.
  • Analysis of clinical trial data for live attenuated and subunit RSV vaccines.
  • Assessment of recombinant technology approaches for RSV vaccine design.

Main Results:

  • Live attenuated RSV vaccines showed varying attenuation; none were sufficiently attenuated for infants.
  • Recombinant technology has enabled numerous candidate vaccines with mutations and gene deletions.
  • Clinical evaluations are ongoing for various candidate vaccines, including subunit vaccines like purified F glycoprotein and F/G/M protein combinations.

Conclusions:

  • Significant advancements in RSV vaccine development have occurred in the last decade.
  • Different RSV vaccines may be required for distinct at-risk populations.
  • Continued research is crucial for developing safe and effective RSV vaccines.
Abstract

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...